Therefore, {HEAD ~ better AR inhibitors} with more potent antagonistic activities and {TAIL ~ minimal agonistic activities} are needed to delay disease progression and to treat the fatal hormone refractory prostate cancer 
with
Therefore , { HEAD ~ better AR inhibitors } with more potent antagonistic activities and { TAIL ~ minimal agonistic activities } are needed to delay disease progression and to treat the fatal hormone refractory prostate cancer
OTH OTH HEAD HEAD HEAD HEAD HEAD HEAD HEAD REL OTH OTH OTH OTH OTH TAIL TAIL TAIL TAIL TAIL TAIL TAIL OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH